Literature DB >> 21777176

Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment.

Chih-Chiang Chien1, Hsien-Yi Wang, Jhi-Joung Wang, Wei-Chih Kan, Tsair-Wei Chien, Ching-Yih Lin, Shih-Bin Su.   

Abstract

OBJECTIVES: Gadolinium-based contrast media (Gd-CM) are reported to induce acute kidney injury (AKI) in a high-risk population group at the usual dose for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) examinations. We assessed gadolinium-induced nephropathy in patients with renal impairment who underwent MRI or MRA examinations, and evaluated the risk factors.
MATERIALS AND METHODS: In this retrospective study, 238 patients with baseline renal impairment, who received MRI or MRA examinations with Gd-CM, were recruited. After all other AKI causes-liver decompensation, severe heart failure, all kinds of shock, and severe sepsis-and patients on dialysis were excluded, 158 patients were enrolled. AKI was defined as a decrease in glomerular filtration rate (GFR) >10% of baseline data within 3 days after administration of Gd-CM. Regression analysis was used to find independent risk factors for gadolinium-induced AKI (Gd-AKI).
RESULTS: Twenty-six of the 158 patients (16.5%) developed Gd-AKI. There were no significant differences in gender, age, or baseline GFR between those who did and who did not develop AKI. Comorbid coronary artery disease, liver cirrhosis, diabetes mellitus, and hypertension were not significantly associated with the development of Gd-AKI. However, sepsis was an independent risk factor for Gd-AKI after multivariate regression analysis (adjusted odds ratio: 4.417; 95% confidence interval: 1.671-11.676, p = 0.03).
CONCLUSIONS: It is potential AKI after administration of Gd-CM under sepsis condition at the dose for MRI and MRA examinations in patients with renal impairment. It is important to identify high-risk patients and closely monitor renal function after administration of Gd-CM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777176     DOI: 10.3109/0886022X.2011.599911

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  10 in total

1.  Non-contrast-enhanced magnetic resonance angiography is equal to contrast-enhanced multislice computed tomography for correct aortic sizing before transcatheter aortic valve implantation.

Authors:  Peter Bernhardt; Christoph Rodewald; Julia Seeger; Birgid Gonska; Dominik Buckert; Michael Radermacher; Vinzenz Hombach; Wolfgang Rottbauer; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2015-09-22       Impact factor: 5.460

2.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

3.  One-Step Preparation of Highly Stable Copper-Zinc Ferrite Nanoparticles in Water Suitable for MRI Thermometry.

Authors:  Dorota Lachowicz; John Stroud; Janusz H Hankiewicz; River Gassen; Angelika Kmita; Joanna Stepień; Zbigniew Celinski; Marcin Sikora; Jan Zukrowski; Marta Gajewska; Marek Przybylski
Journal:  Chem Mater       Date:  2022-04-20       Impact factor: 10.508

4.  Dialysis search filters for PubMed, Ovid MEDLINE, and Embase databases.

Authors:  Arthur V Iansavichus; R Brian Haynes; Christopher W C Lee; Nancy L Wilczynski; Ann McKibbon; Salimah Z Shariff; Peter G Blake; Robert M Lindsay; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-23       Impact factor: 8.237

5.  Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model.

Authors:  Michael S Petronek; Emily J Steinbach; Amanda L Kalen; Zachariah J Builta; Cameron M Callaghan; Dan E Hyer; Douglas R Spitz; Ryan T Flynn; John M Buatti; Vincent A Magnotta; Diana Zepeda-Orozco; Joël J St-Aubin; Bryan G Allen
Journal:  Radiat Res       Date:  2021-03-01       Impact factor: 2.841

Review 6.  Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.

Authors:  Divine C Nwafor; Allison L Brichacek; Afroz S Mohammad; Jessica Griffith; Brandon P Lucke-Wold; Stanley A Benkovic; Werner J Geldenhuys; Paul R Lockman; Candice M Brown
Journal:  J Cent Nerv Syst Dis       Date:  2019-04-09

Review 7.  An Updated Review of Toxicity Effect of the Rare Earth Elements (REEs) on Aquatic Organisms.

Authors:  Nemi Malhotra; Hua-Shu Hsu; Sung-Tzu Liang; Marri Jmelou M Roldan; Jiann-Shing Lee; Tzong-Rong Ger; Chung-Der Hsiao
Journal:  Animals (Basel)       Date:  2020-09-16       Impact factor: 2.752

8.  Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

Authors:  Gilbert Deray; Olivier Rouviere; Lorenzo Bacigalupo; Bart Maes; Thierry Hannedouche; François Vrtovsnik; Claire Rigothier; Jean-Marie Billiouw; Paolo Campioni; Joaquin Ferreiros; Daniel Devos; Daniel Alison; François Glowacki; Jean-Jacques Boffa; Luis Marti-Bonmati
Journal:  Eur Radiol       Date:  2012-12-05       Impact factor: 5.315

9.  Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury.

Authors:  Ebru Gok Oguz; Ahmet Kiykim; Kenan Turgutalp; Refik Olmaz; Onur Ozhan; Necati Muslu; Mehmet Horoz; Simge Bardak; Mehmet Ali Sungur
Journal:  Med Sci Monit       Date:  2013-11-06

10.  Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury.

Authors:  Stephan Ehrmann; Julie Helms; Aurélie Joret; Laurent Martin-Lefevre; Jean-Pierre Quenot; Jean-Etienne Herbrecht; Dalila Benzekri-Lefevre; René Robert; Arnaud Desachy; Fréderic Bellec; Gaëtan Plantefeve; Anne Bretagnol; Auguste Dargent; Jean-Claude Lacherade; Ferhat Meziani; Bruno Giraudeau; Elsa Tavernier; Pierre-François Dequin
Journal:  Ann Intensive Care       Date:  2019-09-23       Impact factor: 6.925

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.